Table 1
PatientDiseaseNY-ESO-1 mRNANY-ESO-1 antibodyHLA-A allelesHLA-DR alleles
MZ19Melanoma++A2DRB1*0101
NW14Melanoma++A2DRB1*0101, 0102, 0104
DRB1*0801, 0803, 0806, 0810
NW29MelanomaUnknown+A2DRB1*1501–1505; 1601–1603; 1605
DRB1*0701
DRB4*0101–0103
DRB5*0101
NW37Melanoma++A2DRB1*1401; 1407–1408; 0901
DRB3*0201–0203
DRB4*0101–0103
NW408Melanoma++A2DRB1*0101, 0102, 0104
DRB3*0201–0202, 0301
DRB*1101, 1104, 1106, 1108–1113
NW690Sarcoma++A2DRB1*1501–1505; 1601–1603; 1605
DRB1*0801; 0803; 0806; 0810
DRB5*0101
NW731Melanoma++A2DRB1*0101
DRB1*1501–1505
NW38Melanoma++A2DRB1*0101; 0701
DRB4*0101–0103
NW-MEL-38Melanoma+NAA2DRB1*0101; 0701
(cell line)DRB4*0101–0103
  • NY-ESO-1 mRNA expression in tumor tissues, status of NY-ESO-1–specific serum antibody, and HLA typing of eight tumor patients and melanoma cell line NW-MEL-38. NA, not applicable.